Seres Therapeutics Stock In The News

MCRB Stock  USD 21.64  4.98  29.89%   
Our overall analysis of Seres Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Seres Therapeutics. The specific impact of Seres Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Seres Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Seres Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Seres Therapeutics Backtesting and Seres Therapeutics Hype Analysis.
For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.

Seres Therapeutics Today Top News and Investor Outlook

seekingalpha News
Seres Therapeutics GAAP EPS of $0.94 beats by $0.52, revenue of $0.35M
https://seekingalpha.com/news/4515573-seres-therapeutics-gaap-eps-of-0_94-beats-by-0_52-revenue-of-0_35m?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Neutral
Macroaxis News: globenewswire.com
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
https://www.globenewswire.com/news-release/2025/10/29/3176257/0/en/Seres-Therapeutics-Receives-Award-of-Up-to-3-6-Million-from-CARB-X-to-Develop-Liquid-Formulation-of-SER-155.html
 Bullish
nasdaq News
Goldman Sachs Group Reaches Analyst Target Price
https://www.nasdaq.com/articles/goldman-sachs-group-reaches-analyst-target-price-0
 Bullish
Macroaxis News: globenewswire.com
Seres Therapeutics Announces Further Con...
https://www.globenewswire.com/news-release/2025/09/23/3154527/0/en/Seres-Therapeutics-Announces-Further-Constructive-Feedback-from-FDA-on-SER-155-Phase-2-Study-Protocol-and-Implements-Cost-Reduction-Actions-to-Extend-Cash-Runway.html
 Bullish
seekingalpha News
QuantumScape rallies as Seeking Alpha analyst pitches the upside
https://seekingalpha.com/news/4494136-quantumscape-rallies-as-seeking-alpha-analyst-pitches-the-upside?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Bullish
seekingalpha News
Rapport Therapeutics prices $250M stock at $26 per share
https://seekingalpha.com/news/4493596-rapport-therapeutics-prices-250m-stock-at-26-per-share?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Bullish
nasdaq News
Biotech Stocks Surge After Hours: CAPR, TMDX Lead Gains Amid Trial Updates And Earnings Momentum
https://www.nasdaq.com/articles/biotech-stocks-surge-after-hours-capr-tmdx-lead-gains-amid-trial-updates-and-earnings
 Bullish
seekingalpha News
Rapport launches proposed public offering of common stock
https://seekingalpha.com/news/4493152-rapport-launches-proposed-public-offering-of-common-stock?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Bullish
seekingalpha News
Seres Therapeutics soars on report of takeover offer
https://seekingalpha.com/news/4493023-seres-therapeutics-soars-on-report-of-takeover-offer?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Bullish
news
Top movers in Monday's pre-market session
https://www.chartmill.com/news/GGAL/Chartmill-34109-Top-movers-in-Mondays-pre-market-session
 Bullish

Seres Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Seres and other traded companies coverage with news coverage. We help investors stay connected with Seres headlines for the 19th of November to make an informed investment decision based on correlating the impacts of news items on Seres Stock performance. Please note that trading solely based on the Seres Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Seres Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Seres Therapeutics investors visualize upcoming and past events in order to time the market based on Seres Therapeutics noise-free hype analysis.

Seres Therapeutics Investors Sentiment

The influence of Seres Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Seres. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Seres Therapeutics' public news can be used to forecast risks associated with an investment in Seres. The trend in average sentiment can be used to explain how an investor holding Seres can time the market purely based on public headlines and social activities around Seres Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Seres Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Seres Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Seres Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Seres Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Seres Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Seres Therapeutics' short interest history, or implied volatility extrapolated from Seres Therapeutics options trading.
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:
Check out Seres Therapeutics Backtesting and Seres Therapeutics Hype Analysis.
For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.92)
Earnings Share
0.88
Revenue Per Share
0.04
Quarterly Revenue Growth
(0.93)
Return On Assets
(0.40)
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.